CANbridge Presents CAN106 Phase 1 Data at European Hematology Association 2022 Congress

BEIJING & CAMBRIDGE, Mass., May 13, 2022–(BUSINESS WIRE)–CANbridge Pharmaceuticals, Inc. (HKEX:1228), a China-based global biopharmaceutical company committed to the research, development and commercialization of transformative therapies for rare diseases and rare oncology, announced that data from the CAN106 phase 1 trial will be presented at the European Hematology Association Congress 2022 in Vienna, Austria, on June 10e

Poster Details:

Title: A Phase 1 Single Ascending Dose Study of CAN106, a Long-acting Anti-C5 Complement Monoclonal Antibody in Clinical Development for PNH and Other Complement-Mediated Diseases

Abstract code: P822

Time and date: Friday June 10, 4:30 PM – 5:45 PM CEST

Authors: Chin Meng Khoo1Charlene Song2Qizhen Wuu2Gerry Cox2

preferences:
1. Department of Medicine, National University Hospital, Singapore
2. Clinical Development and Medical Affairs, CANbridge Pharmaceuticals.

Summaries are available on the EHA website: https://ehaweb.org/congress/eha2022-hybrid/eha2022-congress/.

About CANbridge Pharmaceuticals Inc.

CANbridge Pharmaceuticals Inc. (HKEX:1228) is a China-based global biopharmaceutical company committed to the research, development and commercialization of transformative therapies for rare diseases and rare oncology. CANbridge has a differentiated drug portfolio, with three approved drugs and a pipeline of 11 assets, targeting common rare diseases and rare oncology indications with unmet needs and significant market potential. These include Hunter syndrome and other lysosomal storage disorders, complement mediated disorders, hemophilia A, metabolic disorders, rare cholestatic liver diseases and neuromuscular diseases, as well as glioblastoma multiforme. CANbridge is also building the development of next-generation gene therapy capabilities through a combination of collaboration with leading researchers and biotech companies and in-house capabilities. CANbridge’s global partners include: Apogenix, GC Pharma, Mirum, Wuxi Biologics, Privus, UMass Chan Medical School and LogicBio.

For more information about CANbridge Pharmaceuticals Inc. to: www.canbridgepharma.com.

Forward-Looking Statements

The forward-looking statements in this article speak only as of the date on which the statements in this article are made. Except as required by law, we assume no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the data on which the statements are made or to respond to the occurrence of unanticipated events. You should read this article in its entirety and understand that our actual future results or performance could differ materially from what we expect. In this article, statements of or references to our intentions or those of any of our directors or our company are made as of the date of this article. Each of these intentions may change in light of future developments.

Check out the source version at businesswire.com: https://www.businesswire.com/news/home/20220512005738/en/

Contacts

Investor Relations:
US
Chris Brinzey
ICR Westwicke
[email protected]

China
CANbridge Pharmaceuticals Inc.
[email protected]

Media:
Deanne Eagle
Planet Communication
[email protected]
917.837.5866

Leave a Comment